Premium
Altered pattern of cytokine production by peripheral blood CD2+ cells from B chronic lymphocytic leukemia patients
Author(s) -
Reyes Eduardo,
Prieto Alfredo,
Carrión Flavio,
GarcíaSuarez Julio,
Esquivel Fatima,
Guillén Cristina,
AlvarezMon Melchor
Publication year - 1998
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199802)57:2<93::aid-ajh1>3.0.co;2-w
Subject(s) - cytokine , chronic lymphocytic leukemia , immunology , tumor necrosis factor alpha , medicine , interferon gamma , lymphocyte , interleukin 4 , leukemia , biology
To determine if activation‐induced cytokine production is altered in CD2+ lymphocytes from B‐CLL patients, cytokine levels were determined by ELISA in supernatants of PHA‐stimulated cultures of CD2+ cells from 33 B‐CLL patients and 22 healthy controls. The production of Interferon γ (IFN‐γ) and Tumor Necrosis Factor (TNF‐α) by mitogen‐activated CD2+ lymphocytes from B‐CLL patients was higher than that found in healthy controls, while no differences were found in TNF‐β production. IFN‐γ and TNF‐α levels determined at 72 h in PHA‐stimulated CD2+ cell cultures from B‐CLL patients statistically correlated with the percentages of CD3+CD45RO+ and CD3−CD56+ lymphocytes, respectively. Although there were differences in the production kinetics of interleukins (ILs) 2 and 4 between B‐CLL patients and the healthy controls, no differences were found at the time when the levels of both interleukins peak. The production of both IFN‐γ and IL‐4 by PHA‐stimulated CD2+ lymphocytes from non‐smouldering B‐CLL patients was significantly higher than that from smouldering B‐CLL patients while no significant differences were found in the production of IL‐2, TNF‐α, and TNF‐β between the two B‐CLL patient groups. These data suggest that functional alterations in the production of cytokines by CD2+ cells from B‐CLL patients could help to explain the expansion of leukemic cells in B‐CLL patients. Am. J. Hematol. 57:93–100, 1998. © 1998 Wiley‐Liss, Inc.